Loss of Mediator complex subunit 13 (MED13) promotes resistance to alkylation through cyclin D1 upregulation

Alkylating drugs are among the most often used chemotherapeutics. While cancer cells frequently develop resistance to alkylation treatments, detailed understanding of mechanisms that lead to the resistance is limited. Here, by using genome-wide CRISPR–Cas9 based screen, we identify transcriptional M...

Descripción completa

Detalles Bibliográficos
Autores principales: Roliński, Miłosz, Montaldo, Nicola Pietro, Aksu, Merdane Ezgi, Fordyce Martin, Sarah L, Brambilla, Alessandro, Kunath, Nicolas, Johansen, Jostein, Erlandsen, Sten Even, Liabbak, Nina-Beate, Rian, Kristin, Bjørås, Magnar, Sætrom, Pål, van Loon, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Genome Integrity, Repair and Replication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897519/
https://www.ncbi.nlm.nih.gov/pubmed/33444446
http://dx.doi.org/10.1093/nar/gkaa1289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897519/
https://www.ncbi.nlm.nih.gov/pubmed/33444446
http://dx.doi.org/10.1093/nar/gkaa1289

Ejemplares similares